⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658238 | 0.82 | TDP1 (0.36) | — | |
| SCHEMBL5090365 | 0.75 | — | — | |
| SCHEMBL4282536 | 0.75 | — | — | |
| SCHEMBL3679158 | 0.75 | — | — | |
| SCHEMBL28046279 | 0.73 | — | — | |
| SCHEMBL6073322 | 0.73 | TDP1 (0.38) | — | |
| Methacrylic Acid SCHEMBL9895773 | 0.73 | TP53 (0.40) | — | |
| SCHEMBL7778435 | 0.73 | SLC7A5 (0.40) | — | |
| SCHEMBL5586687 | 0.72 | — | — | |
| SCHEMBL255878 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240075150-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | ASCENDIS PHARMA A/S (DK) | 2024-03-07 | — | — | US | claimed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | claimed |
| EP-4218795-A2 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | Ascendis Pharma Bone Diseases A/S (DK) | 2023-08-02 | — | — | EP | claimed |
| EP-4192508-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | Ascendis Pharma A/S (DK) | 2023-06-14 | — | — | EP | claimed |
| US-20230110994-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2023-04-13 | — | — | US | claimed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | claimed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | claimed |
| EP-4084872-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | Ascendis Pharma A/S (DK) | 2022-11-09 | — | — | EP | claimed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | claimed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | claimed |
| US-9561285-B2 | Carrier-linked carbamate prodrug linkers | ASCENDIS PHARMA AS (DK) | 2017-02-07 | — | — | US | claimed |
| WO-2016196124-A2 | PRODRUGS COMPRISING A PYROGLUTAMATE LINKER | ASCENDIS PHARMA INC. (US) | 2016-12-08 | — | — | WO | claimed |
| WO-2016110577-A1 | CNP PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2016-07-14 | — | — | WO | claimed |
| US-20160089446-A1 | Modified Hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-31 | — | — | US | claimed |
| CN-103450772-A | Organic silicon modified epoxy acrylic acid high anticorrosion heat insulation paint and production method thereof | BOYIFEI EQUIPMENT INST FOR NEW MATERIALS | 2013-12-18 | — | — | CN | claimed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | claimed |
| EP-2459225-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | claimed |
| CN-102260365-A | Acrylic ester resin solution and preparation method thereof | — | 2011-11-30 | — | — | CN | claimed |
| WO-2011012723-A1 | INJECTABLE SUSTAINED RELEASE COMPOSITIONS COMPRISING A PRAMIPEXOLE PRODRUG | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |
| WO-2011012721-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | claimed |